News Releases

Printer friendly version

Protox strengthens senior management team

Wednesday, June 29, 2005 - Vancouver, British Columbia - Protox Therapeutics Inc. announced today that Leonard Cox, B.Sc., CA, has been appointed Chief Financial Officer and Vice President of Operations.

"We are pleased to have an experienced biotechnology executive join Protox at this critical phase as we advance our platform technology from discovery research into human clinical development," said Dr. Fahar Merchant, President & CEO of the Company. "Leonard brings an outstanding track record from Xenon Pharmaceuticals where he was part of the senior management team that built the company into one of British Columbia's leading life science enterprises."

Mr. Cox obtained his Chartered Accountant designation in 1994 and has held roles of increasing responsibility in the biotechnology, high technology and manufacturing industries. Prior to joining Protox, he was Vice President, Finance at Xenon Pharmaceuticals Inc. During his five year tenure at Xenon, Mr. Cox was actively involved in negotiating a US$157 million partnership and equity investment with Novartis AG, completing a CDN$87 million collaboration and licensing agreement with Pfizer Inc. and raising over CDN$100 million in VC and institutional financings. Prior to Xenon, Mr. Cox held the position of Corporate Controller at Avcorp Industries. He holds a B.Sc. in Biochemistry and Genetics from the University of Witwatersrand in South Africa and is a member of the Institute of Chartered Accountants of British Columbia.

ABOUT PROTOX: Protox Therapeutics Inc. is developing novel therapeutics for the treatment of cancer and other indications by engineering the naturally occurring bacterial toxin Aerolysin, which kills cells by forming pores in them. The Company believes that its engineering approach will produce targeted therapeutics that may have greater efficacy and fewer side effects than existing treatments.

For more information, contact:
Terry Vanderkruyk
Director, Investor Relations, Protox Therapeutics Inc.
Tel: 604-688-4376
Cell: 604-789-0844
Fax: 604-688-0173
tvanderkruyk@protoxtherapeutics.com